B cells and B cell directed therapies in CNS inflammation

B08

B cells are an important therapeutic target in MS. While anti-CD20 therapy (depleting B cells) is beneficial in MS, targeting the B cell survival factors B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) with atacicept worsened MS. The reasons for this apparent paradox are unclear, but indicate that the BAFF-APRIL system influences MS in a way that has not yet been understood. We aim to investigate the molecular and cellular basis of mechanism of action of different B cell directed therapies that are currently in use or being developed. In detail, we intend to analyze effects of different B cell directed therapies in peripheral and intrathecal compartments both in MS patients and in B cell dependent animal models including a spontaneous disease model featuring formation of autoantibodies and a Th17 adoptive transfer model featuring formation of submeningeal ectopic lymphoid follicles. These questions will guide our research::

    1. Why did blocking of BAFF and APRIL by atacicept worsen MS?
    2. What are the mechanistic details of anti-CD20 therapy?
    3. Inhibition of Bruton’s Tyrosine Kinase (BTK) is a promising novel therapeutic strategy in MS. How does the inhibition of BTK influence neuroinflammation?

 

 

 

 

 

 

 

 

 

 

 

Laurent et al., Nat Commun., 2015

 

Principal Investigators:

Prof. Dr. med. Edgar Meinl
Institut für klinische Neuroimmunologie
LMU München
edgar.meinl@med.uni-muenchen.de

Dr. rer nat. Anneli Peters
Institut für klinische Neuroimmunologie
LMU München
anneli.peters@med.uni-muenchen.de

News

Mon, 09/05/2022
Scientific Retreat including public Webinar
Muenster. For the first time after a longer pandemic-related break, the SFB 128 will host an onsite retreat. On Thursday and Friday, 23 and 24 June, the participating scientists will meet in Muenster to present the current status and developments of their projects. The event is also an opportunity for the exchange and the discussion […]...more
Wed, 19/01/2022
One drug – different effects: Metabolism of immune cells influences mode of action and could be an indicator for side effects
Muenster – One person can eat large amounts of pasta and still be a small dress size while another looks at a piece of chocolate and puts on weight: metabolism varies between individuals – and this goes beyond a subjective feeling. What is apparent in the overall organism also applies to each cell: the metabolism […]...more
Tue, 14/12/2021
Save the date: 2nd Inflammation & Imaging Symposium
Münster. Save the date: 12-14 September 2022! We cordially invite you to join this international symposium, jointly organized by the research networks CRC 1450, CRC 1009, CRC 1348, CRU 342, CRC/TR 128 and the Cells in Motion Interfaculty Centre at the University of Münster. At the same time, we will officially open the new research […]...more